Grant D
University Campus, London Health Sciences Center, London, Ontario, Canada.
Lancet. 1996 Jun 29;347(9018):1801-3. doi: 10.1016/s0140-6736(96)91619-0.
Intestinal transplantation is an alternative to total parenteral nutrition (TPN) for the treatment of chronic intestinal failure. To determine the current status of small-bowel transplantation, we have reviewed the world experience since 1985.
We built up an international registry by asking twenty-five intestinal transplantation programmes to submit standard data on their cases operated on between 1985 and June, 1995.
One centre (two transplantations) did not use our report form, and these cases were excluded. The remaining twenty-four programmes did 180 transplantations in 170 patients. Two-thirds of the recipients were children. The main indication (64 percent) was short-gut syndrome, another 13 percent had a tumour. Of the grafts, 38 percent were small-bowel with or without colon, 46 percent were intestine plus liver, and 16 percent were multivisceral. Graft/patients' survival (percent) at 1 and 3 years under cyclosporin immunosuppression was, respectively: 17/57 and 11/50 for small bowel only; 44/44 and 28/28 for intestine plus liver; and 41/41 and 41/41 for multiviscera. The corresponding figures under tacrolimus were: 65/83 and 29/47; 64/66 and 38/40; and 51/59 and 37/43. 78 percent of the 86 survivors had stopped TPN and resumed oral nutrition.
Our approach cannot give data on long-term outcome. The short-term results of intestinal transplantation are similar to those of lung grafting. We conclude that small-bowel transplantation has become a life-saving option for patients who cannot be maintained on TPN and for those who require massive abdominal evisceration for locally aggressive tumours.
肠移植是治疗慢性肠衰竭的全胃肠外营养(TPN)替代方法。为确定小肠移植的现状,我们回顾了1985年以来的全球经验。
我们通过要求25个肠移植项目提交1985年至1995年6月期间其手术病例的标准数据,建立了一个国际登记处。
一个中心(2例移植)未使用我们的报告表,这些病例被排除。其余24个项目对170例患者进行了180例移植。三分之二的受者为儿童。主要适应证(64%)为短肠综合征,另有13%患有肿瘤。在移植物中,38%为带或不带结肠的小肠,46%为肠加肝,16%为多脏器联合移植。在环孢素免疫抑制下,1年和3年时移植物/患者生存率(%)分别为:仅小肠移植为17/57和11/50;肠加肝移植为44/44和28/28;多脏器联合移植为41/41和41/41。他克莫司治疗下的相应数据为:65/83和29/47;64/66和38/40;51/59和37/43。86名存活者中有78%停止了TPN并恢复了口服营养。
我们的方法无法提供长期结果数据。肠移植的短期结果与肺移植相似。我们得出结论,小肠移植已成为无法通过TPN维持的患者以及因局部侵袭性肿瘤需要进行大面积腹部脏器切除的患者的一种挽救生命的选择。